# Windtree Therapeutics Inc. (WINT)

Source: https://www.quantisnow.com/company/WINT
Generated: 2026-11-08T07:52:03.773Z

- Ticker: WINT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- SEC CIK: 0000946486
- Website: windtreetx.com

## About

Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.

## Latest WINT news and filings

- 2026-09-10 20:10 UTC [Public Offering] [TransCode Therapeutics Announces Leadership Transition](https://www.quantisnow.com/insight/transcode-therapeutics-announces-leadership-transition-6711613)
- 2026-07-21 21:50 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6644387)
- 2026-04-01 15:57 UTC [SEC Form NT 10-K filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-k-filed-by-windtree-therapeutics-inc-6481396)
- 2026-01-07 21:53 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-leadership-update-6341479)
- 2025-12-23 14:00 UTC [Mergers & Acquisitions] [Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates](https://www.quantisnow.com/insight/windtree-therapeutics-announces-the-sale-of-its-cardiovascular-biotech-pipeline-6326337)
- 2025-12-03 14:00 UTC [Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space](https://www.quantisnow.com/insight/windtree-therapeutics-announces-it-has-signed-a-letter-of-intent-6300961)
- 2025-12-02 21:31 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-creation-of-a-6299872)
- 2025-11-21 13:15 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-windtree-therapeutics-inc-6289758)
- 2025-11-19 22:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-windtree-therapeutics-inc-6287354)
- 2025-11-17 14:00 UTC [Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee](https://www.quantisnow.com/insight/windtree-therapeutics-announces-it-may-receive-license-agreement-payments-from-6282333)
- 2025-11-14 21:13 UTC [SEC Form NT 10-Q filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-windtree-therapeutics-inc-6280560)
- 2025-11-14 14:00 UTC [Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate](https://www.quantisnow.com/insight/windtree-therapeutics-announces-more-strengthening-of-its-istaroxime-and-next-6279235)
- 2025-11-13 14:00 UTC [Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company](https://www.quantisnow.com/insight/windtree-therapeutics-announces-it-will-receive-75-million-in-cash-6276510)
- 2025-11-13 13:01 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-windtree-therapeutics-inc-6276265)
- 2025-10-24 20:09 UTC [SEC Form S-1] [SEC Form S-1 filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-windtree-therapeutics-inc-6244575)
- 2025-10-16 21:04 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-creation-of-a-6236016)
- 2025-10-06 18:27 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6224411)
- 2025-09-08 21:16 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-leadership-update-6193713)
- 2025-09-02 21:16 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6186333)
- 2025-09-02 13:00 UTC [Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting](https://www.quantisnow.com/insight/windtree-therapeutics-stockholders-approve-key-proposals-for-revenue-and-profit-6185217)
- 2025-08-20 16:15 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6173214)
- 2025-08-19 21:29 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-windtree-therapeutics-inc-6172272)
- 2025-08-14 21:01 UTC [SEC Form NT 10-Q filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-nt-10-q-filed-by-windtree-therapeutics-inc-6166970)
- 2025-08-11 13:00 UTC [Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025](https://www.quantisnow.com/insight/windtree-announces-istaroxime-has-been-chosen-for-a-plenary-session-6157702)
- 2025-08-08 21:08 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-windtree-therapeutics-inc-6156822)
- 2025-08-08 20:54 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-other-events-6156752)
- 2025-08-05 20:43 UTC [SEC Form 3] [SEC Form 3 filed by new insider Kucharchuk Andrew Albert](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-kucharchuk-andrew-albert-6147966)
- 2025-08-05 13:05 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6146651)
- 2025-08-05 13:00 UTC [Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients](https://www.quantisnow.com/insight/windtree-announces-istaroxime-phase-2-interim-analysis-in-scai-stage-6146605)
- 2025-08-04 20:31 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-leadership-update-6145127)
- 2025-07-29 13:01 UTC [Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption](https://www.quantisnow.com/insight/windtree-therapeutics-announces-large-reduction-of-preferred-series-c-and-6135701)
- 2025-07-24 13:05 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6131120)
- 2025-07-24 13:00 UTC [Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy](https://www.quantisnow.com/insight/windtree-therapeutics-announces-up-to-520-million-in-new-funding-6131069)
- 2025-07-22 13:00 UTC [Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services](https://www.quantisnow.com/insight/kraken-and-windtree-therapeutics-announce-strategic-partnership-for-bnb-custody-6127831)
- 2025-07-17 13:24 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6123376)
- 2025-07-16 13:22 UTC [Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions](https://www.quantisnow.com/insight/windtree-to-launch-bnb-crypto-treasury-strategy-with-agreement-for-6121668)
- 2025-07-14 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-windtree-therapeutics-inc-6118461)
- 2025-07-10 13:23 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-windtree-therapeutics-inc-6116516)
- 2025-07-07 20:55 UTC [SEC Form S-1] [Amendment: SEC Form S-1/A filed by Windtree Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-1a-filed-by-windtree-therapeutics-inc-6112941)
- 2025-07-03 18:26 UTC [SEC Form 8-K] [Windtree Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/windtree-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6110640)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/WINT
- Earnings history: https://www.quantisnow.com/earnings/WINT
- Dividend history: https://www.quantisnow.com/dividends/WINT
- Insider transactions: https://www.quantisnow.com/insiders/WINT
- Options chain: https://www.quantisnow.com/options/WINT
- SEC 8-K filings only: https://www.quantisnow.com/company/WINT/8-k
- RSS and alerts for WINT: https://www.quantisnow.com/docs/rss-feeds.md